Patient Summit USA 2016

eyeforpharma 10 - 11 October 2016, Sonesta Philadelphia, USA.
The 13th annual Patient Summit USA 2016 is where patient-driven partnerships with stakeholders actually happen. This is not just a talking shop - be one of 300+ senior pharma executives, regulatory authorities, providers, payers, advocates and patients who plan to deliver sustainable solutions to the patient community.

Patient Centricity ...so what?

  • Streamline cultural change by setting a universal framework for patient centricity
  • Prove ROI-driven patient initiatives and get internal buy-in
  • Hear directly from patients and caregivers and mend their disconnect with the industry
  • Overcome roadblocks to advocacy and adherence with an enhanced focus on access programs
  • Navigate a complex regulatory environment while still promoting your patient initiatives

Turn profit-patient into patient-profit
Transforming your profit-patient model into a patient-profit system is one of the biggest shake-ups in pharma's history.

Many major brands are already in the process of creating and developing a new patient-centric approach, and introducing measures to reward staff against patient-oriented metrics.

What was once an 'if?' has become a 'when and how?'. But changing an engrained mind-set requires a collaborative effort; the more companies that encourage–and in some cases enforce–patient-centricity, the more widespread the buy-in will be.

'Profit' is still a valid talking point - it hasn't become a dirty word. What has changed is that it is now being seen as a natural by-product of putting patients first.

Now that patients are being almost universally regarded as pivotal to the sustained growth of pharma, the question turns back to: how will an inverted model still provide profit for pharma and key stakeholders?

The conference aims to help pharma stakeholders share views, and examine ways to put patients at the centre of evolving pharma business models, without damaging profits. Putting patients first needs to be attractive on both the humanistic and fiscal levels in order for patient centricity to thrive.

World Pharma News readers can benefit from an exclusive discount code, save €200 using World Pharma News unique code WorldPharma200

For further information, please visit:
http://www.eyeforpharma.com/patientusa/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...